ATH 3.13% 3.1¢ alterity therapeutics limited

+ + data and comment + +

  1. 22,691 Posts.
    7.15 mill shares issued at 70 cents and about $5 mil was raised taking cash holdings to $7 mill.:


    "On 5 August 2003 Prana announced that its highly successful medicinal chemistry program had created a library of approx. 300 compounds specifically engineered to address age-related neurodegenerative diseases such as Alzheimers Disease.

    From these compounds the Company’s technical review committee selected an NCE (New Chemical Entity) which has been code-named

    PBT-2 to advance to human clinical trials. This follows the successful completion of Prana’s recent proof of concept trial utilising clioquinol (PBT-1), an existing off-label drug previously prescribed for a non-related application.

    PBT-2 is a new proprietary compound developed by Prana scientists to specifically target Alzheimers Disease.

    It is owned exclusively by Prana and has significantly outperformed PBT-1 in the laboratory and animal trials undertaken to date.

    Given the success of the previous human trials of PBT-1 the Board of Prana and its scientists approach the clinical phase of PBT-2 with heightened confidence".
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $64.60M
Open High Low Value Volume
3.1¢ 3.1¢ 3.1¢ $205.0K 6.615M

Buyers (Bids)

No. Vol. Price($)
11 2658968 3.1¢

Sellers (Offers)

Price($) Vol. No.
3.2¢ 968790 6
View Market Depth
Last trade - 16.10pm 16/04/2021 (20 minute delay) ?
-0.001 ( 6.06 %)
Open High Low Volume
3.1¢ 3.1¢ 3.1¢ 749580
Last updated 15.57pm 16/04/2021 (live) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.